COVID-19 Pandemic Stops Phase 2 Trial of Ficlatuzumab Combo Therapy for AML
News
The Phase 2 CyFi-2 study assessing the safety and efficacy of ficlatuzumab (previously AV-299) combined with standard chemotherapy in patients with hard-to-treat acute myeloid leukemia (AML) has been discontinued due ... Read more